We speculated that the STAT6 mutant protein plays a role in therapeutic resistance, however, we found that STAT6D419A/G/H/N mutations in GCB-DLBCL cells have no impact on cellular response to the individual components of R-CHOP. Here, STAT6 is linked to diffuse large B-cell lymphoma.